Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Section Content Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Safety

  • Print
  • Share
  • E-mail
-

Neupogen (filgrastim)

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CBER)

 

May 2012

Summary View

ADVERSE REACTIONS

Postmarketing Experience
  • decreased bone density and osteoporosis in pediatric SCN patients

PATIENT PACKAGE INSERT

What about pregnancy or breast-feeding?

  • If you become pregnant during NEUPOGEN  treatment, you are encouraged to enroll in Amgen’s Pregnancy Surveillance Program. You should call 1-800-77-AMGEN (1-800-772-6436) to enroll

How to Prepare the dose of Neupogen in Vials or Prefilled Syringes ..... section updated

 

 

June 2010

Summary View

PRECAUTIONS

Pregnancy Category C
  • Women who become pregnant during Neupogen treatment are encouraged to enroll in Amgren's Pregnancy Surveillance Program.  Patients or their physicians should call 1-800-77-AMGEN (1-800-772-6436) to enroll.

 

-
-